Prime Medicine (PRME) KOL Event summary

Introduction and agenda

• Event focused on liver disease franchise strategy, particularly Wilson disease, leveraging prime editing technology for durable cures, and included market opportunity, treatment landscape, preclinical data, and clinical plans.

• Agenda featured presentations from management and a key opinion leader, review of preclinical data, clinical development plans, milestones, and Q&A.

• Virtual event scheduled for November 12, 2025, to discuss strategy and development plans.

KOL background and credentials

• Dr. Michael Schilsky, Professor of Medicine at Yale and leading hepatologist, provided clinical insights on Wilson disease pathology, diagnosis, and management.

Market insights and analysis

• Wilson disease represents a significant unmet need with no curative therapies; current treatments are burdensome, have low compliance, and significant side effects.

• Estimated 25,000–26,000 addressable patients in US, Europe, and Japan, with 300 new cases annually.

• Commercial opportunity estimated at $20–40 billion globally.